Russia's Pharmsynthez to launch major production of hormonal preparations

24 September 2021

Pharmsynthez (MISK: LINE), one of Russia’s leading drugmakers, is planning to launch one of the largest productions of hormonal preparations in Russia, which will be located the city of Tyumen by November of the current year.

So far, the main construction works for the plant have been completed, while the equipment is being commissioned. The value of investments is estimated at 4 billion roubles ($55 million).

As a representative of the company told Russia’s Deputy Prime Minister Yuri Borisov during his visit to the plant, the new production will be able to meet a significant part of Russia’s annual needs in hormonal drugs. The drugs that will be produced at the new plant will be generics that will be manufactured under licenses from Germany’s Bayer (BAYN: DE) and Hungary’s Gedeon Richter (RICHT: HB).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK